Solvay Articles
Stock Commentary Europe
14 April 1999
Stock Commentary Tokyo
14 April 1999
Fluvoxamine is first SSRI cleared in Japan
13 April 1999
UK Vaccines Industry Group set up
7 April 1999
UK Vaccines Industry Group set up
6 April 1999
Fluvoxamine set to be first SSRI in Japan
11 March 1999
Meiji Seika goes abroad to strengthen R&D
26 February 1999
Solvay aims to expand pharma business
16 February 1999
New Solvay chief in Canada
11 February 1999
New indication for Solvay's Prometrium - updated story
7 January 1999
FDA approves Solvay's Prometrium
22 December 1998
Merger And Acquisition Prospects In Japan
7 December 1998
Stock Commentary Europe
17 September 1998
Solvay Hopes To Grow Further in USA & Asia
15 September 1998
Moxonidine In CHF
10 September 1998
American Home Pharma Sales Up 7% For 2nd Qtr
22 July 1998
Solvay CEO Against Large Alliances
16 June 1998
Solvay's Prometrium Cleared In USA
21 May 1998
Stock Commentary Europe
23 April 1998
23% Rise In Pharma Earnings At Solvay
16 April 1998
US Investor Group Acquires Hungarian Research Institute
14 April 1998
Solvay In Polish Production JV
26 March 1998
US DTC Ad Spend "Now Exceeding Journal Ads"
20 March 1998
Stock Commentary Europe
19 March 1998
Product News In Brief
12 March 1998
Promotions At Solvay
5 March 1998
Stock Commentary Europe
19 February 1998
Expanded Warnings For J&J's Hismanal
11 February 1998
Solvay And Elan Cooperate On ER-Fluvoxamine
6 February 1998
US Court Rules For Solvay In Sage Suit Over Menogen
4 February 1998
Top Firms Maintaining Strong Sales & Profits
13 January 1998
Solvay Files Estratab For Osteoporosis
11 December 1997
Fujisawa Says Global Business Growing Steadily
4 December 1997
EFPIA Expands Membership To Drugmakers
24 November 1997
3rd-Qtr Revenue Rise At Innogenetics
20 November 1997
Solvay's Physiotens Launched In UK
30 October 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Solvay To Increase Pharma Investment
1 October 1997
New Solvay Chief
25 September 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Zoloft Becomes 2nd SSRI Cleared For Panic
23 July 1997
UK Industry Code Of Practice Review
2 July 1997
Appointment At Solvay
19 June 1997
P&U/Solvay's Luvox: Approved For OCD
7 April 1997
Appointments At Solvay USA
17 March 1997
Belgium's Solvay Health Care Unit Does Best
24 February 1997
EUROPEAN AND LONDON STOCK COMMENT
27 January 1997
EUROPEAN AND LONDON STOCK COMMENT
20 January 1997
UK Rx Medicines Code Of Practice Report
20 January 1997
Appointment At Solvay Healthcare
18 November 1996
Appointment At Solvay Seiyaku
4 November 1996
Solvay To Divest Animal Health
30 September 1996
Roll-Out Of Solvay's Physiotens Continues
9 September 1996
Solvay Pharma And SB To Copromote Famvir
19 August 1996
European And London Stock Comment
12 August 1996
Solvay Sees Profits Fall 28% In 1st Half
5 August 1996
Recovery Of Solvay In 1995 Continues In 1996
29 July 1996
World Drug Sales Rise 9% In January 1996
6 May 1996
UK Industry Code of Practice: latest Report
4 March 1996
Solvay Launches Lithobid In USA
12 February 1996
Genencor acquires Solvay industrial enymes business
4 December 1995
European Stock Comment
4 December 1995
Solvay Sets Up Deals With Arqule, Cadus
13 November 1995
TheraTech/Solvay Collaborate On New HRT
6 November 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Solvay Pharmaceuticals appointments
18 September 1995
Solvay appointment
11 September 1995
First-half results for Solvay
11 September 1995
Duphar Name Change
19 June 1995
Solvay Recovers In 1994
24 April 1995
Two More Launches For Upjohn's Freedox
24 April 1995
Mood Disorders Market Set To Grow To $9.5 Bill By 2004
27 March 1995
Solvay Forecasts Profits For 1994
20 February 1995
Polarization Concerns For Chemical/Drug Majors?
16 January 1995
B-MS' Nefazodone: Launch Soon In USA
9 January 1995
Solvay Gains Luvox Approval From FDA
19 December 1994
SB's Seroxat Better Tolerated Than Faverin?
5 December 1994
Fluvoxamine Relief For Compulsive Shoppers
21 November 1994
Solvay Agreement With B-MS
31 October 1994
Solvay Launches Lithobid In USA
3 October 1994
Luvox Approvable For OCD In USA
12 September 1994
SOLVAY RESULTS
8 August 1994
European Stock Comment
8 August 1994
SOLVAY AGREEMENT
25 July 1994
EUROPE STOCK COMMENT
13 June 1994
SOLVAY EXPECTS RECOVERY
13 June 1994
EUROPEAN STOCK COMMENT
30 May 1994
NEW PLAYER IN US DEPRESSION MARKET
25 April 1994
SOLVAY POSTS LOSS FOR 1993
25 April 1994
BTG'S PSORIASIS DRUG TO BE SOLD BY J&J
7 March 1994
SOLVAY INVESTS IN JAPANESE UNIT
7 February 1994
NEW APPROVALS CHANGE DEPRESSION MARKET
17 January 1994
ENVIRONMENTAL MOVES BY SOLVAY
10 January 1994
EXPANDING PHARMA MARKET IN TURKEY
10 January 1994
DUPHAR JOINS UK DRUGS BRIBERY ROW
29 November 1993
OCD PATIENTS RESPOND TO FLUVOXAMINE
1 November 1993
SOLVAY MAKES 1993 FIRST-HALF LOSS
9 August 1993
FDA ACTS ON KABI MISLEADING AD CLAIMS
9 August 1993
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
